Form 4: Roivant Sciences CEO Matthew Gline Sells Shares to Cover Tax Obligations

Roivant Sciences CEO Matthew Gline sold 11,623 common shares to cover tax obligations related to the vesting of restricted stock units.

Summary

• Matthew Gline, CEO of Roivant Sciences Ltd., sold 11,623 common shares on January 20, 2025.
• The sale was executed at a price of $11.15 per share.
• This transaction was a 'net settlement' by the company to cover tax withholding obligations related to the vesting of previously granted restricted stock units (RSUs).
• Following the transaction, Matthew Gline directly owns 17,327,546 common shares.

Sentiment

Score: 7

Explanation: The document reflects a routine transaction related to executive compensation. It is neither particularly positive nor negative for the company's outlook.

Industry Context

This is a routine transaction for executives who receive equity compensation. It is common for companies to withhold shares to cover taxes when RSUs vest.

Comparison to Industry Standards

• The sale of shares to cover tax obligations is a standard practice among publicly traded companies.
• Many executives at companies like Pfizer, Moderna, and Regeneron regularly sell shares to cover taxes related to equity compensation.
• The number of shares sold and the price are within the typical range for such transactions.

Stakeholder Impact

• The transaction has a minimal impact on shareholders as it is a routine sale to cover tax obligations.
• The sale does not indicate any change in the executive's confidence in the company.

Key Dates

Keywords

Roivant Sciences, Matthew Gline, share sale, insider trading, Form 4, tax obligations, restricted stock units, RSUs, net settlement